{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:37:58Z","timestamp":1763037478390},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s11883-020-00859-3","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T07:03:46Z","timestamp":1594796626000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The State of Percutaneous Intervention in Stable Coronary Artery Disease"],"prefix":"10.1007","volume":"22","author":[{"given":"Caitlin","family":"Drescher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil V.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,15]]},"reference":[{"key":"859_CR1","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1161\/01.CIR.99.21.2829","volume":"99","author":"RJ Gibbons","year":"1999","unstructured":"Gibbons RJ, Chatterjee K, Daley J, et al. ACC\/AHA\/ACP\u2013ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). Circulation. 1999;99:2829\u201348.","journal-title":"Circulation."},{"key":"859_CR2","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1161\/CIRCOUTCOMES.114.000967","volume":"7","author":"PS Chan","year":"2014","unstructured":"Chan PS, Jones PG, Arnold SA, Spertus JA. Development and validation of a short version of the Seattle Angina Questionnaire. Circ Cardiovasc Qual Outcomes. 2014;7:640\u20137.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"3","key":"859_CR3","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1161\/circ.54.3.947585","volume":"54","author":"L Campeau","year":"1976","unstructured":"Campeau L. Gradient of angina pectoris. Circulation. 1976;54(3):522\u20133.","journal-title":"Circulation."},{"issue":"8","key":"859_CR4","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.jacc.2016.06.005","volume":"68","author":"S Bansilal","year":"2016","unstructured":"Bansilal S, Castellano JM, Garrido E, Wei HG, Freeman A, Spettell C, et al. Assessing the impact of medication adherence on long-term cardiovascular outcomes. JACC. 2016;68(8):789\u2013801.","journal-title":"JACC."},{"key":"859_CR5","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa1915922","volume":"382","author":"DJ Maron","year":"2020","unstructured":"\u2022\u2022 Maron DJ, Hochman JS, Reynolds HR, et al. Initial invasive or conservative strategy for stable coronary disease. NEJM. 2020;382:1395\u2013407 The ISCHEMIA trial demonstrates no significant difference in cardiovascular mortality between an initial invasive strategy and optimal medical therapy for stable ischemic heart disease.","journal-title":"NEJM"},{"key":"859_CR6","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1056\/NEJMoa070829","volume":"356","author":"WE Boden","year":"2007","unstructured":"Boden WE, O\u2019Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. NEJM. 2007;356:1503\u201316.","journal-title":"NEJM."},{"key":"859_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(17)32714-9","volume":"391","author":"R Al-Lamee","year":"2018","unstructured":"\u2022 Al-Lamee R, Thompson D, Dehbi HM, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018;391:31\u201340 This trial reports no improvement in exercise time six weeks after PCI for stable ischemic heart disease when compared with medical therapy.","journal-title":"Lancet"},{"key":"859_CR8","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1916370","volume":"382","author":"JA Spertus","year":"2020","unstructured":"\u2022\u2022 Spertus JA, Jones PG, Maron DJ, et al. Health-status outcomes with invasive or conservative care in coronary disease. NEJM. 2020;382:1408\u201319 Ischemic symptoms improved significantly with an invasive strategy as compared with optimal medical therapy for patients in the ISCHEMIA trial.","journal-title":"NEJM"},{"key":"859_CR9","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa1505532","volume":"373","author":"SP Sedlis","year":"2015","unstructured":"Sedlis SP, Hartigan PM, Teo KK, Maron DJ, Spertus JA, Mancini GB, et al. Effect of PCI on long-term survival in patients with stable ischemic heart disease. NEJM. 2015;373:1937\u201346.","journal-title":"NEJM."},{"key":"859_CR10","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ahj.2018.04.011","volume":"201","author":"DJ Maron","year":"2018","unstructured":"Maron DJ, Hochman JS, O\u2019Brien SM, et al. International study of comparative health effectiveness with medical and invasive approaches (ISCHEMIA) trial: rationale and design. AHJ. 2018;201:124\u201335.","journal-title":"AHJ."},{"issue":"24","key":"859_CR11","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1161\/01.CIR.103.24.2928","volume":"103","author":"GJ Bech","year":"2001","unstructured":"Bech GJ, De Bruyne B, Pijls NH, et al. Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis: a randomized trial. Circulation. 2001;103(24):2928\u201334.","journal-title":"Circulation."},{"key":"859_CR12","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1093\/eurheartj\/ehv452","volume":"36","author":"FM Zimmermann","year":"2015","unstructured":"Zimmermann FM, Ferrara A, Johnson NP, van Nunen LX, Escaned J, Albertsson P, et al. Deferral vs. performance of percutaneous coronary intervention of functionally non-significant coronary stenosis: 15-year follow-up of the DEFER trial. EHJ. 2015;36:3182\u20138.","journal-title":"EHJ."},{"key":"859_CR13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa0807611","volume":"360","author":"PAL Tonino","year":"2009","unstructured":"Tonino PAL, De Bruyne B, Pijls NH, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. NEJM. 2009;360:213\u201324.","journal-title":"NEJM."},{"key":"859_CR14","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(15)00057-4","volume":"386","author":"LX van Nunen","year":"2015","unstructured":"van Nunen LX, Zimmerman FM, Tonino PA, et al. Fractional flow reserve versus angiography for guidance of PCI in patients with multivessel coronary artery disease (FAME): 5-year follow-up of a randomised controlled trial. Lancet. 2015;386:1853\u201360.","journal-title":"Lancet."},{"key":"859_CR15","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1161\/CIRCULATIONAHA.117.031907","volume":"137","author":"WF Fearon","year":"2018","unstructured":"\u2022 Fearon WF, Nishi T, De Bruyne B, et al. Clinical outcomes and cost-effectiveness of fractional flow reserve-guided percutaneous coronary intervention in patients with stable coronary artery disease. Circulation. 2018;137:480\u20137 The FAME 2 trial shows lower rates of MACE and anginal symptoms in patients with stable CAD and FFR\u2009\u2264\u20090.80 after PCI as compared with optimal medical therapy.","journal-title":"Circulation"},{"key":"859_CR16","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1161\/CIRCULATIONAHA.118.033801","volume":"138","author":"R Al-Lamee","year":"2018","unstructured":"Al-Lamee R, Howard JP, Shun-Shin MJ, et al. Fractional flow reserve and instantaneous wave-free ratio as predictors of the placebo-controlled response to percutaneous coronary intervention in stable single-vessel coronary artery disease. Circulation. 2018;138:1780\u201392.","journal-title":"Circulation."},{"key":"859_CR17","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1700445","volume":"376","author":"JE Davies","year":"2017","unstructured":"Davies JE, Sen S, Dehbi HM, al-Lamee R, Petraco R, Nijjer SS, et al. Use of the instantaneous wave-free ratio or fractional flow reserve in PCI. NEJM. 2017;376:1824\u201334.","journal-title":"NEJM."},{"key":"859_CR18","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1161\/CIRCULATIONAHA.119.042918","volume":"140","author":"RK Al-Lamee","year":"2019","unstructured":"Al-Lamee RK, Shun-Shin MJ, Howard JP, et al. Dobutamine stress echocardiography ischemia as a predictor of the placebo-controlled efficacy of percutaneous coronary intervention in stable coronary artery disease. Circulation. 2019;140:1971\u201380.","journal-title":"Circulation."}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-020-00859-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-020-00859-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-020-00859-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T00:28:45Z","timestamp":1626308925000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-020-00859-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,15]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["859"],"URL":"https:\/\/doi.org\/10.1007\/s11883-020-00859-3","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,15]]},"assertion":[{"value":"15 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Sunil Rao reports modest research funding to Duke University Health System from Bayer Inc, Svelte Inc., and Shockwave Medical Inc. for his roles as principal investigator or on steering committees. Dr. Rao is an interventional cardiologist.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"42"}}